Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines

초록

PurposeTo determine the effects of botulinum toxin type A (BTX-A) injection on dry eye signs, symptoms, and tear cytokine levels in patients with intractable dry eye disease (DED).MethodsIn this prospective study, patients with intractable DED were randomized to a BTX-A (group A) or control group (group B). Patients were injected with BTX-A or normal saline in the medial part of the upper and lower eyelids. Before and at 2weeks, 1month, 2months, and 4months after injection, dry eye signs; tear film break-up time (TBUT), Schirmer I test, corneal fluorescein staining (CFS), and symptoms; ocular surface disease index (OSDI); and frequency of lubricants were assessed. The tear levels of matrix metalloproteinase (MMP)-9 and serotonin were measured before and at 1month after injection.ResultsFifty-two eyes from 26 patients (mean age, 57.7years) were included. The TBUT was higher at 2weeks and at 1month in group A. The Schirmer I test and OSDI scores were also better in group A for up to 2months. The CFS grades in group A were significantly lower until 4months. Repeated measures analysis of variance (RMANOVA) demonstrated significant differences between the two groups over time for the Schirmer I test (p=0.002), CFS (p=0.025), OSDI (p=0.020), and frequency of lubricants (p=0.029). The MMP-9 conversion rate of group A (76.92%) was significantly higher than that of group B (38.46%, p=0.005). The tear serotonin level in group A was reduced from 2.760.34 to 1.73 +/- 0.14ng/mL (p<0.001). No complications were observed during the study.Conclusion p id=Par4 BTX-A injection into the medial part of eyelid improves dry eye signs and symptoms and reduces tear cytokine levels. BTX-A is thus a potential treatment option for patients with intractable DED.

키워드